Extracorporeal magnetotransduction therapy (EMTT) delivers a high-intensity, rapidly oscillating magnetic field through a loop applicator into a volume of tissue. The changing field induces a secondary electrical field inside the tissue — the same physics behind pulsed electromagnetic field (PEMF) therapy, but at far higher intensity: EMTT devices typically run around 80 millitesla, roughly 10–80 times the field strength of a standard PEMF unit. That induced field is thought to raise VEGF (vascular endothelial growth factor), promoting local blood flow, and to modulate inflammatory signaling in the treated tissue.
It is not a shockwave. ESWT works mechanically, as a pressure pulse traveling through tissue. EMTT works electromagnetically, with no mechanical pulse at all — patients typically don’t feel it the way they feel a shockwave session.
| ESWT (Focused/Radial) | EMTT | |
|---|---|---|
| Energy | Acoustic pressure wave | Oscillating magnetic field |
| Sensation | Mechanical impact, often felt | Painless, no mechanical sensation |
| Reach | Set by focal depth or decays from the applicator | Penetrates broadly through a treatment volume |
| Proposed effect | Mechanotransduction — fibroblast/ECM remodeling, cavitation-driven neovascularization | Electrotransduction — VEGF-driven angiogenesis, anti-inflammatory signaling, cellular metabolism |
Because the two work through different physical mechanisms, they’re often paired rather than substituted for each other: ESWT for a discrete mechanical target (a tendon insertion, a fibrotic band), EMTT for a broader degenerative or inflamed joint volume where a focused mechanical pulse isn’t the right tool.
The best current evidence is a 2026 double-blind, sham-controlled randomized trial by Hollander and colleagues, published in the Journal of Back and Musculoskeletal Rehabilitation. It enrolled 126 patients across three conditions — knee osteoarthritis (31), rotator cuff enthesopathy (43), and lumbar spondyloarthrosis (52) — randomized to eight weekly 20-minute EMTT sessions (80 mT, 8 Hz, 10,000 pulses per session) or an identical-feeling sham.
At 12 weeks, the EMTT group reported significantly less pain (VAS 2.2 vs. 4.2, p<0.001) and better physical function (SF-12 PCS 45.5 vs. 38.7, p<0.001) than sham. Mental-health scores didn’t differ between groups.
Worth being direct about the trial’s limits, because they matter: follow-up stopped at 12 weeks, there were no imaging or biomarker endpoints, it was a single-center trial with a mixed patient population, and 46% of the sham group believed they’d received active treatment — a reminder that a real placebo response is baked into any pain-outcome trial like this one. The authors themselves note there isn’t yet a body of systematic reviews on EMTT the way there is for ESWT. It’s one well-designed, sham-controlled trial — good evidence, not exhaustive evidence.
2026 double-blind sham-controlled EMTT RCT:
Hollander et al., Journal of Back and Musculoskeletal Rehabilitation, 2026 — PubMed
Full text on Sage
Novo uses EMTT for the conditions the evidence actually covers: degenerative and inflamed joint tissue and enthesis pain — knee osteoarthritis, rotator cuff enthesopathy, and lumbar spondyloarthrosis (facet-joint driven low back pain) are the three conditions studied directly in the Hollander trial. It’s not a substitute for treating a mechanically adhered tendon or fascia — that’s what focused or radial ESWT and manual release are for.
EMTT is paired with focused ESWT when the exam finds the problem sitting in a joint or a deep muscle compartment rather than at a single, accessible tendon insertion. The magnetic field doesn’t cause the mechanical impact sensation of a shockwave pulse — patients typically don’t feel EMTT sessions the way they feel ESWT.
As with every tool at Novo, EMTT is used when the exam says it belongs, not as a default add-on to every visit.